Two decades after women held few leadership roles in the life sciences industry, their presence has grown significantly, particularly in the Boston-Cambridge biotech hub. The emergence of the Biotech CEO Sisterhood, a global network founded in 2022 with about 350 members—100 of whom are based in Massachusetts—reflects this shift. These women lead companies at various stages, from startups to established publicly traded firms, including notable figures such as Julie Kim of Takeda, Dr. Reshma Kewalramani of Vertex Pharmaceuticals, Dr. Yvonne Greenstreet of Alnylam Pharmaceuticals, and Daphne Zohar of Seaport Therapeutics.
Women’s advancement extends beyond executive roles in companies to influential positions in industry groups, venture capital, and banking. Kendalle Burlin O’Connell heads MassBio, the leading life sciences trade organization in the region, while venture capitalists like Yvonne Hao of Flagship Pioneering and Tess Cameron of RA Capital play key roles in funding innovation. Efforts to support women in leadership often trace back to mentorship legacies established by early champions like the late Henri Termeer, former Genzyme CEO, who fostered a culture encouraging female leadership.
Despite gains, challenges remain. A 2017 MassBio report highlighted that although women entered the life sciences workforce in similar numbers to men, they were underrepresented in senior management and board roles—only one in four women reached the C-suite, and just one in ten sat on boards. This lack of representation was underscored by industry events like the 2018 J.P. Morgan Healthcare Conference and the BIO International Convention in Boston, where all-male panels were common and certain promotional activities sparked controversy.
In response, companies increased efforts to promote gender equity, with some, like Sanofi, setting ambitious targets to achieve gender parity in senior leadership. This year, Sanofi appointed Dr. Belén Garijo as its first female CEO, marking a milestone in corporate leadership. Alongside her, Julie Kim became Takeda’s first female CEO, underscoring a growing trend of women reaching the highest positions in major biotech companies.
Industry dynamics also play a role. The recent "biotech winter," influenced by regulatory uncertainty and fluctuating research funding, challenged the sector, yet the biotech industry has rebounded with new breakthroughs and investments, creating fresh opportunities for women to found and lead companies. Many rising women leaders exhibit a willingness to change jobs or launch startups when career advancement stalls, signaling a more assertive generation determined to break through barriers. Seaport Therapeutics, for example, is led by Daphne Zohar and features a majority-female senior leadership and board, illustrating how women at the top are shaping company cultures around diversity and excellence.
Nevertheless, some experts caution that progress remains fragile. Women still hold just 12 percent of CEO positions among the largest publicly traded biopharmaceutical companies in the United States. Moreover, recent merger and acquisition data indicate a decline in deals led by women, raising concerns about the durability of the momentum toward gender equity. Abbie Celniker, a partner at Third Rock Ventures, noted that while advancements have been made, sustainable change requires ongoing commitment in the face of rising opposition to diversity initiatives.
Reflecting on the journey, pioneers like Deborah Dunsire recall early support from male leaders who recognized the need for cultural shifts, crediting these efforts with helping women penetrate leadership ranks. The formation of supportive networks like the Biotech CEO Sisterhood and increased visibility of female executives contribute to changing perceptions, providing newer generations of women with role models and opportunities. As Boston’s life sciences sector continues to evolve, the mixed picture of progress and challenges underscores the importance of sustained focus on diversity and inclusion in biotech leadership.